- By Gina Chiri-Osmond
Mayo Clinic Launches First-in-U.S. Blood Test that Assesses Risk of Heart Attack Using Plasma Ceramides
ROCHESTER, Minn. — Mayo Clinic has launched a new type of blood test that will be used to predict adverse cardiovascular events in patients with progressing coronary artery disease (CAD). The test measures blood concentrations of plasma ceramides, a class of lipids that are highly linked to cardiovascular disease processes. Researchers say this test is especially useful for patients with CAD when it does not improve with treatment or for young patients with premature CAD.
The new test will help clinicians identify at-risk individuals and is available to Mayo Clinic patients and health care providers worldwide through Mayo Medical Laboratories (MML). MML is the reference laboratory of Mayo Clinic, offering advanced laboratory testing and pathology services to more than 5,000 health care organizations in more than 60 countries. MML collaborated on the test with Zora Biosciences Oy, a diagnostics discovery company based in Finland that specializes in cardiovascular disease.
“Through our strong collaboration with Zora Biosciences, we hope our new test will improve the evaluation of individuals at risk for cardiovascular disease,” says Jeff Meeusen, Ph.D., a clinical chemist and co‑director of Cardiovascular Laboratory Medicine at Mayo Clinic. “This test is for patients with highly specialized cases, for example, patients with progressing coronary artery disease — despite treatment and control of their risk factors, or for younger individuals with premature CAD.”
The test also might be used to determine if treatment is necessary in individuals at intermediate risk via the risk calculator from the American College of Cardiology and the American Heart Association.
MEDIA CONTACT: Gina Chiri-Osmond, Mayo Clinic Public Affairs, 507-284-5005, firstname.lastname@example.org
“Plasma ceramides are promising biomarkers for the prediction of adverse CV events in either primary and/or secondary prevention. The studies to date suggest that the signals observed presage events within the next five-year period,” says Allan Jaffe, M.D., cardiologist at Mayo Clinic and chair of the Division of Clinical Core Laboratory Services, with joint appointments in the Department of Cardiovascular Diseases and the Department of Laboratory Medicine and Pathology. “Risk conferred by plasma ceramides appears to be independent of other established and novel biomarkers, and there are preliminary indications that high ceramide concentrations can be modified by common lipid-lowering therapies.”
About the Plasma Ceramides Test (Test ID: CERAM)
The test for plasma ceramides is to be used in conjunction with clinical evaluation and patient risk assessment as an aid in predicting risk of imminent adverse cardiovascular events. Risks conferred by ceramides are independent of traditional biomarkers including age, sex, smoking status, and history of CAD. In a study published in 2016 in European Heart Journal, plasma ceramides were found to predict the likelihood of an adverse cardiovascular event within one year in CAD patients. In patients with suspected CAD and/or chronic heart failure, the test can predict the likelihood of an event within three to five years, based on studies published in Canadian Journal of Cardiology and the International Journal of Epidemiology.
About Zora Biosciences
Zora Biosciences, based in Espoo, Finland, is a diagnostics discovery company specializing in cardiovascular diseases. Zora Biosciences identifies robust markers of disease and develops them into high-throughput, health-economic, value-added clinical methods. For more information, visit the company’s website at www.zora.fi.
About Mayo Medical Laboratories/Department of Laboratory Medicine and Pathology
The Mayo Clinic Department of Laboratory Medicine and Pathology and its reference laboratory Mayo Medical Laboratories provide advanced laboratory testing and pathology services to support 5,000 health care organizations around the world. Revenue from this testing is used to support medical education and research at Mayo Clinic, a nonprofit worldwide leader in medical care, research, and education for people from all walks of life. Complemented by collaborations with diagnostic and biotechnology companies, the department maintains a robust diagnostic test-development program, launching more than 150 new tests each year.
About Mayo Clinic
Mayo Clinic is a nonprofit organization committed to clinical practice, education, and research, providing expert, whole-person care to everyone who needs healing. For more information, visit http://www.mayoclinic.org/about-mayo-clinic or https://newsnetwork.mayoclinic.org/.